Abstract We studied the induction of antigen-specific lgA memory B cells (BM) in volunteers who received live attenuated Shigella flexneri 2a vaccines. Subjects ingested a single oral dose of 10 7 , 10 8 or 10
Introduction
Shigella infections continue to be a major cause of morbidity and mortality among children under 5 years old living in the developing world. Every year, there are 165 million cases of shigellosis worldwide and 14,000 cases reported in the United States; it is estimated that because of underreporting, the number of actual cases may be twenty times higher [1.2] . The increasing prevalence of resistance to multiple antimicrobials is of concern [3] and Shigella is considered a Category B bioterror agent by the CDC [4] . Shigella flexneri is endemic throughout the developing world, and causes more mortality than any other species of Shigella [5] . There is a high demand for a safe and effective oral vaccine, and the WHO has prioritized the development of a well· tolerated vaccine that induces durable immunity against shigellosis [1, 6] .
By engineering rational deletions in the wild-type S. flexneri 2a strain 2457 T, two vaccine candidates, designated CVD 1204 and CVD 1208, were constructed at the Center for Vaccine Development (CVD). CVD 1204 contains deletions in guaA (encoding a guanosine monophosphate synthase) and guaB (encoding an inositol monopho· sphate dehydrogenase), which impair the biosynthesis of guanine nucleotides; CVD 1208 has additional deletions of set and sen genes that encode Shigella enterotoxins 1 and 2, respectively. In a Phase 1 trial CVD 1204 was shown to be clearly attenuated compared to its wild type parent (based on comparison with data from multiple previous challenge studies), while CVD 1208 appeared fully attenuated yet immunogenic [7] . Clinical adverse reactions (diar· rhea, dysentery and/or fever) occurred in 8 of 23 recipients of CVD 1204 but in only 1 of 21 recipients of CVD 1208 [7] .
Putative correlates of protection against shigellosis reported in the literature include serum lgG antibodies against lipopolysaccharide (LPS) 0 antigen and serotype specific 0 antigen peripheral blood lgA antibody secreting cells (ASC) [2, 8, 9] . Other antibody and cell-mediated immune responses (CMI) against conserved antigens such as invasion plasmid antigens (lpa) may also play a role in protective immunity [2, [10] [11] [12] [13] ]. An optimal vaccine should not only induce enduring systemic and mucosal antibody responses but also allow the host to mount an anamnestic immune response upon subsequent re·exposure to antigen. This response is faster, stronger, and qualitatively better than primary responses and depends on the presence of BM cells [14] . Following natural Shigella infection, as well as after ingestion of some live attenuated Shigella vaccines, relatively long-term humoral and second· ary secretory lgA immune responses to LPS in stool have been described [15] . We have previously demonstrated the induction of lgG BM responses by live attenuated Shigella vaccines in human volunteers [16] . However, the presence of lgA BM responses has not been reported. In this study we examined the hypothesis that volunteers who display mucosal and serum antibody responses to CVD 1204 and CVD 1208 live-attenuated oral Shigella vaccines also exhibit lgA BM cell responses specific to LPS, lpaB and other Shigella antigens.
Materials and Methods

1. Specimens
46 healthy adult volunteers 18-45 years of age from the BaltimoreWashington area received a single oral dose of S. flexneri 2a t:.guaBA (CVD 1204) or S. flexneri 2a t:.guaBA !Jsen !Jset (CVD 1208) as previously described [7] . Volunteers received 10 7 , 1 rf', or 10 9 CFU of each vaccine strain or placebo, and sera and stools were collected on days 0, 7, 14, 28, and 42. In addition, peripheral blood mononuclear cells (PBMC) were obtained on days 0 and 28 after oral vaccination. PBMC specimens were cryopreserved and stored in liquid nitrogen until use as previously described [17] . Seroresponse, measured by ELISA [7] , was defined as24-fold rise of antigen-specific lgA antibody in serum (serorespon· ders) and a 24-fold rise of antigen-specific lgA/total lgA in stool J.K. Simon et al.
(mucosal responders) after oral vaccination as compared to prevaccination. Adequate specimens were available to assay 13 seror· esponders and 11 non-seroresponders; these included subjects immunized with placebo or 10 7 , 10 8 , or 10 9 CFU of the Shigella strains.
For BM assays, subjects from all three dosage level cohorts were analyzed. Prior to enrollment, the purpose of the study was explained to the subjects and they passed a written test containing questions regarding the rationale for the study, risks and procedures. Informed consent was obtained from all participants and the study was approved by the UMD Institutional Review Board.
Antigen Preparation
LPS was purified by the hot aqueous phenol method of Westphal [18] . lpaB, lpaC, lpaD, MxiH, VirG and Yersinia pestis LcrV antigens were purified as recombinant proteins from Escherichia coli. A PCR fragment of virG encompassing amino acids 68-774 was copied from the vir plasmid of S. flexneri 2457 T by standard PCR. The fragment was ligated into pET22b (Novagen, Madison, WI) and the ligation product used to transform f. coli NovaBlue. The resulting plasmid was sequenced and used in the protein expression system. I paD, VirG and LcrV were purified by standard His tag chromatography and dialyzed into PBS as described previously [19, 20] . lpaC and MxiH were solubilized from inclusion bodies with 6 M urea, purified by standard His tag chromatography, and refolded by step dialysis into PBS as previously described [21, 22] . lpaB was co-expressed with its cognant chaperone, lpgC, as described previously [23] . The complex was purified by standard His tag chromatography via the His tag fused to the lpgC. lpaB was released from lpgC with 1% n-octyl· polyoxyethylene.
Mucosal and Systemic Antibodies
Serum antibodies specific for S. flexneri LPS and lpa B were measured by ELISA as we previously described [7] . Briefly, plates were coated with LPS (5 11g/mL) or lpaB (0.1 flg/mL) and blocked with 10% dried milk in PBS. Samples were evaluated in serial 2-fold dilutions. HRP-labeled goat anti-human Fe a chain (ICN) was used as conjugate and TMB microwell Peroxidase (Kirkegaard & Perry Laboratories, KPL) as substrate. Titers were calculated from linear regression curves as the reciprocal serum dilution that produced an OD of 0.2 above the blank (EU/mL). Total and LPS-specific fecallgA were also measured by ELISA as previously described [7] . Plates were coated with either a-chain specific anti-human lgA (1 11g/mL; Jackson lmmunoResearch Laboratories) or LPS (10 flg/mL). Stool supernatants were tested in serial2·fold dilutions. HRP·labeled goat anti-human lgA (Jackson) was used as conjugate and TMB (KPL) as substrate. lgA concentrations were calculated by interpolation into a standard curve of human lgA (Calbiochem). Data are reported as the ratio of LPS-specific/ totallgA levels.
Antibody Secreting Cells
lgA and lgG ASCs specific for 5. flexneri LPS and lpaB were detected by ELl Spot as we previously described [7 ,24] . A positive ASC response was defined as a post-vaccination count at least 3 SD above the mean prevaccination count and at least 8 cells/ 10 6 PBMC.
PBMC Expansion
Expansion of PBMC to measure BM cells was performed as described by Crotty et al. [25] . Briefly, PBMC specimens were thawed, washed with complete cRPMI1640 containing 100 IU/mL penicillin, 100 flg/ mL streptomycin (CellGro, Manassas, VA), 2 mM L-glutamine (BiDWhittaker, Walkersville, MD), and 10% heat-inactivated fetal bovine pestis LcrV (as a negative control) or 5 ).lg/ml of mouse anti-human lgA in PBS and incubated overnight at 4 'C. The plates were then blocked with 1% bovine serum albumin (Sigma) in RPMI for 2 hat 37' C and 5% C0 2 , and 10 5 expanded PBMC added per well coated with LPS, lpaB, lpaC, !paD, VirG, MxiH or LcrV. For total lgA measure· ments, serial 2-fald dilutions were perfanmed starting at 7500 expanded cells/well down to 234 cells/well. Cells were incubated for 5 hat 37' C and 5% C0 2 , washed with PBST followed by PBS, and incubated with mouse anti-human pan lgA Biotin Conjugated Antibody (Hybridoma Reagent Laboratory, Baltimore, MD) overnight at 4 'C. Subsequently plates were washed with PBST and PBS and labeled with horseradish peroxidase-conjugated Avidin D (Vector Laboratories, Burlingame, CA) for 1 h at room temperature. The substrate 3-Amino-9 etheylcarbazole C (Calbiochem, La Jolla, CA, USA) was added at 100 ).ll per well for 20 minutes at roam temperature and the reaction was stopped with ddH 2 0. Final enumeration of specific and total SFC was performed using the lmmunospot Series 3B Analyzer Ell SPOT reader (Cellular Technolo· gies Ltd, Shaker Heights, OH) with aid of the lmmunospot software version 4.0 (Cellular Technologies Ltd).
Adequate expansion of BM cells, assessed by the frequency of total lgA detected by Ell SPOT, is critical to the sensitivity and consistency of this method. Thus, specimens which did not reach a minimum cut-off level following expansion (arbitrarily defined as the 1Oth percentile of the levels reached by all volunteers at any time point: i.e., >8300/1W totallgA SFC/10 6 expanded cells) were excluded from further analysis. Statistical analysis was performed on the mean number of SFC in antigen-coated wells minus the mean number of SFC in the negative control wells. The limit of detection of antigen-specific/total expanded cells in our assays was 1 in 100,000 (0.001%). The limit of detection of antigen-specific/total lgAsecreting cells in each volunteer was determined by taking into account the maximum number of total lgA SFC for that subject in anti-lgA coated ELISPOT wells. The latter had an acceptable minimum of 0.005% (i.e., 1 specific SFC in the 8300 total lgA SFC/ 10 6 expanded cells cut -off).
Flow Cytometry
Eight volunteers had sufficient PBMC available after expansion pre and post vaccination to enable flow cytometric measurements. Of these subjects, 3 volunteers were responders by LPS lgA in serum and stool by ELISA and 5 were non responders. Of the 3 LPS responders, 2 were also lpaB responders. Expanded PBMC were washed with 1% FBS in PBS and labeled with fluorochrome-labeled mAbs against the following antigens: (1) CD19-ECD (done J3.119, Beckman-Coulter, Fullerton, CA), (2) CD20-APC-Cy7 (clone L27, BD Biosciences, San Jose, CA), (3) CD27-APC-A700 (clone 1A4CD27, Beckman-Coulter), (4) lgA-Biotin (done G20-359, BD Biosciences-subsequently labeled with streptavidin-Pacific Orange (InVitrogen, Carlsbad, CA), (5) 
Results
1. Evaluation of Total and Specific SFC After Expansion of BM Cells
Twenty four volunteers who received vaccine had sufficient PBMC pre-and post-vaccination to be included in these studies. Thirteen of the 24 subjects were anti·LPS lgA seroresponders. All 13 seroresponders were also mucosal responders by slgA anti·LPS measured in stool. Three individuals were mucosal responders only with24 fold increases in anti-LPS/total stool slgA without a serum response. Cells from one anti·LPS seroresponder had to be excluded from analysis due to inadequate expansion. LPS-specific BM cells increased from a median of 7 SFC/10 6 expanded cells prevaccination to a median of 53 SFC/1W expanded cells 28 days post-vaccination (p=0.005) (Fig. 1 ). Increases were observed in LPSspecific lgA BM in 10 out of 12 lgA antHPS (83%) seroresponders with adequate expansion. Of 24 vaccinated volunteers who had sufficient PBMC to perform these studies, 7 also displayed an lgA antHpaB seroresponse. Mean lgA anti-lpaB BM cells increased from 4 to 20 SFC/10 6 expanded cells pre-to post-vaccination (p=0.062); 4 out of 7 (57%) lgA lpaB seroresponders manifested an increase in lgA antilpaB BM cells. The median percentages of antigen-specific SFC as a proportion of total lgA SFC showed increases from 0.03% pre· vaccination to 0.20% post-vaccination for LPS (p value =0.005) and 0.03% pre-vaccination to 0.10% post-vaccination for lpaB (p=0.2) among seroresponders (Fig. 1) . Individuals who were not seroresponders did not exhibit a statistically significant increase in antigen-specific BM responses pre-to post-vaccination.
Because of the importance of other proteins in Shigella pathogenesis, e.g., VirG (lcsA), MxiH, lpaB, lpaC and lpaD [26, 27] , we studied whether immunization with a live oral Shigella vaccine also elicited specific BM to these antigens. Only sporadic BM responses were observed to lpaC, lpaD, MxiH, and VirG. No responses were detected against Y. pestis LcrV {negative control).
The frequency of BM can be quantified as the number of anti-LPS or as antHpaB specific lgA per 10 6 expanded PBMC or the% of anti· LPS or anti·lpaB specific lgA divided by the total number of lgA producing cells in expanded PBMC. As can be observed in Fig. 2 
Correlation of BM Responses with Antibody Responses in Serum and Stool
Mucosal responses to vaccination (i.e., the production of secretory lgA in stool/total ;;::4 fold pre to post oral vaccination) was observed among 16 out of 24 subjects in this study. Among these 16 subjects, strong correlations were observed when comparing their LPSspecific BM {SFC/1cf' expanded cells) frequencies measured on day 28 with their respective post-vaccination peak seroresponse (Fig. 3A) , peak mucosal (stool) lgA response (Fig. 38) , and peak peripheral blood lgA ASC responses (Fig. 3C) . Strong correlations were also observed among anti-LPS lgA BM and both mucosal and peripheral anti·LPS lgA responses among the 12 individuals who were seroresponders (data not shown). Of importance, the correlations remain significant when results were analyzed as percentages of specific antHPS lgA BM divided by total lgA secreting cells in each volunteer. No significant correlations were observed among antibody levels in serum and stool and peripheral BM cells on day 0 (pre· vaccination, data not shown). Calculations taking into account individual spot sizes (a relative measurement of the amount of antibody produced by each cell) did not change the results. Interestingly, no correlations were observed between the levels of lpaB·specific lgA BM cells and the serum levels of antHpaB lgA antibodies or the levels of anti·lpaB ASC in circulation (stool anti· lpaB antibody levels were not measured)(data not shown). Among the vaccine recipients who exhibited a mucosal response, the frequencies of lgA BM cells were better correlated with serum LPS lgA titers (Fig. 3 ) than with serum LPS lgG (Spearman Rho 0.5, p=0.05).
Expression of Gut Homing Molecules in Plasmablasts and BM Following Immunization
Toevaluatewhetherimmunization with CVD 1204 orCVD 1208 resulted in changes in the proportion of B cell subsets of defined phenotypes, The results from these studies demonstrated an increase in lgA secreting cells post-oral vaccination compared to pre-vaccination among the LPS seroresponders. This increase was statistically significant when comparing responders to non-responders by Wilcoxon Rank Sum in the CD19" integrin cq/!)71gA' CD27" CD20' as well as CD19' integrin a 4 11'7 lgA• CD27" CD2() 1 tow subsets (Fig. 4) . No significant differences among responders and non-responders were observed in the percentages of any of the other subsets evaluated (i.e., !gG' subsets, CD19' integrin a.,/1' 7 -subsets, CD19• integrin a4/r1 7 • CD2T CDZO' and CD19' integrin a 4 /[j 7 • CD2T CD20-subsets). 
Discussion
Immune responses induced locally provide the first line of defense against the many pathogens that invade the human host via mucosal surfaces. Humans make more lgA than lgG, lgM and lgE combined and allows for active transport of slgA across mucosal epithelia to facilitate antigen exclusion and neutralization [30] . The normal human colon has a higher proportion of lgA than lgG-producing plasma cells as evidenced by immunohistochemistry [31] . The induction of BM responses is widely accepted to be a major factor in the ability of vaccines to elicit long lasting, effective immunity.
However, the precise role of lgA ASC and BM cells in primary and
secondary [anamnestic] immune responses to infection remains ill defined .
A BM response can be demonstrated by documenting: (1) an anamnestic secondary antibody response, both stronger and faster than the initial immune response, (2) avidity maturation, and (3) the presence of BM cells [32] . BM cells have been described in humans against vaccines known to induce a T-cell dependent response, including live viral vaccines administered parenterally (e.g. small· pox vaccine [33] ) and orally (e.g., rotavirus vaccines [34] ) and parenteral conjugate vaccines consisting of bacterial polysaccharides (such as pneumococcal [35] and meningococcal [36] capsular polysaccharides) covalently linked to carrier proteins. BM cells have also been reported following natural infection with bacterial enteropathogens and after the administration of live oral bacterial enteric vaccines [16, 37] . We here report the observation that oral immunization with attenuated S. flexnerf 2a vaccines elicits the generation specific lgA BM cells .
Although the immunological correlates of protection following Shigella infection have not yet been fully elucidated, high numbers of antigen-specific lgA ASC post oral vaccination have been found to be associated with protection from shigellosis after experimental challenge [8] . Interestingly, the volunteers who have high numbers of antigen-specific ASC after vaccination and are asymptomatic after challenge have low levels of antigen-specific lgA ASC in peripheral blood after secondary antigen exposure [38] . In the present study we observed that a single oral immunization with live attenuated Shigella vaccine CVD 1204 or CVD 1208 elicited significant increases in antigen-specific lgA anti-LPS BM responses among subjects who mounted 2 fourfold specific slgA or lgA antibody responses as measured by ELISA, respectively, in stool and serum. lpaB seroresponders also exhibited antigen-specific lgA BM responses to lpaB. Strong correlations were observed between the magnitude of lgA anti·LPS BM cells and increases in anti·LPS lgA responses, both among individuals who displayed a strong mucosal slgA stool response and among lgA seroresponders. BM cells also correlated highly with anti-LPS lgA ASC, both among seroresponders and mucosal responders. It will be important to determine in future experimental challenge studies with wild-type Shigella whether antigen-specific lgA and lgG BM cells are elevated in subjects who had been (or not) previously immunized with oral live attenuated Shigella strains and whether BM cells are associated with protection.
We were surprised that no differences were detected in the magnitude of BM cell responses among recipients of the slightly reactogenic CVD 1204 or the very well tolerated CVD 1208, or related to the various dosage levels evaluated (1 0 7 , 10 8 , or 10 9 CFU). An optimistic interpretation of this observation is that the loss of reactogenicity resulting in a well tolerated further attenuated Shigella vaccine strains such as strain CVD 1208 is not accompanied by a diminution of the ability to elicit strong immune responses, including the generation of antigen-specific lgA BM cells.
In previous studies we determined by flow cytometry the proportions of phenotypically defined total B, BM and lgG• BM cell populations before and after expansion [16] . This information helped validate the BM cell ELISPOT assay as well as provide the rationale for limiting the analyses to specimens that showed evidence of appropriate in vitro expansion in the presence of mitogens. By eliminating specimens that exhibited suboptimal expansion of functional cells (defined ass8,300 totallgA SFC/1o6 expanded cells) in the current dataset, we observed increased levels of circulating antigen-specific lgA BM responses elicited by oral vaccination of up to 1.1% antigen-specific BM SFC/totallgA SFC postvaccination forT-independent antigen LPS and up to 1.0% for the Tdependent antigen lpaB. These proportions of antigen-specific BM cells are similar to those previously reported in subjects who received efficacious parenteral vaccines. For example, responses to diphtheria and tetanus toxoids elicited specific BM cells over total lgG secreting cells in the range of 0.01-1% [39] . Recombinant hepatitis B vaccine showed the induction of 0.07% hepatitis B surface antigen-specific lg secreting cells over totallg secreting cells; 88% of vaccinees had detectable levels of lgG BM cells and 76% had detectable levels of lgA and lgM BM cells [40] . In natural cholera infection, anti-LPS lgA BM cells have been reported to be 0.6% of total lgA BM cells and proposed to play an important role in the anamnestic mucosal immune response [37] . To our knowledge, the data included in the present manuscript is the first description of the induction of specific lgA BM cell response to LPS in recipients of an oral live-attenuated bacterial vaccine. Since Shigella enters the host via the gut, it is important to define the local immune responses elicited by immunization. Due to regulatory constraints and other factors, intestinal mucosal biopsies are very difficult to obtain following vaccine administration or challenge with wild-type organisms. Alternative ways to investigate whether antigen-specific lgA and lgG ASC and BM found to be elevated in the periphery after oral vaccination have the potential to migrate to the gut mucosa involve indirect measurements, such as slgA in stool and the measurement of gut homing molecule expression, e.g., integrin ot4/r; 7 , on lgA• and lgG• ASC and BM cells. Although in our experience flow cytometry is not as sensitive as ELISPOT in assessing antigen-specific BM responses, it nevertheless allowed us to characterize the phenotype of the B cell subsets that increased following oral vaccination.
In the present study we found significant increases in the . White BM only express surface tg, expression of lg in plasmablasts is largely cytoplasmic with lower levels of surface lg expression [41] . Because this manuscript is focused on BM and sufficient cells were not available for independent staining panels (i.e., extracellular and intracellular lgA and/or lgG staining), we stained extracellularly for lg. Thus, it is likely that the smaller differences observed in integrin a 4 1W7 lgA• plasmablasts in responders as compared to nonresponders are the result of a lower efficiency in the detection of lgG· and lgA• plasmablasts. Future studies using intracellular lg staining will allow this issue to be addressed directly. In contrast to the increases in tgA• cells, this phenomenon was not observed in CD19+ a4/fH lgG BM celts (irrespective of expression of CD27 and/or CD20). In sum, we found that lgA·, but not lgG•, CD19• B cells expressing the gut homing receptor integrin a 4 /f~7 increased 28 days after oral vaccination, and that gating on subsets based on the expression of CD27 and CD20 enhanced the ability to identify this population. This observation is consistent with Crotty's original description of the BM cell ELISPOT where sorting experiments were used to identify that BM have a cozr cozo· phenotype [25] . The present results suggest an increase in circulating Shigella specific lgA BM and plasmablasts with gut homing potential in individuals in whom immunization elicited anti-Shigella humoral responses. A limitation of this study is the relatively small number of volunteers who could be evaluated, which is largely due to the fact that it employed "convenience" specimens based on availability. In spite of this limitation, we observed strong, statistically significant, specific anti-LPS lgA BM responses and associations with anti·LPS lgA antibody and ASC levels. However, it is very likely that the small sample size provided insufficient power to adequately estimate the presence and association of anti-lpaB lgA BM cells and seroresponses. Future studies will address this issue by evaluating larger numbers of subjects and vaccine candidates.
Virulent Shigella target the M cells that overlie gut-associated lymphoid tissue and rapidly attain an intracellular niche within epithelial cells. SlgA anti-Shigella antibodies can prevent mucosal invasion. Moreover, wild type organisms coated with such antibody elicit less profound inflammatory responses than Shigella not coated with antibody [42] . It is not known how long slgA intestinal and serum lgG anti-Shigella antibodies stimulated by clinical infection or oral immunization with Shigella vaccines remain elevated at levels adequate to prevent invasion and clinical illness. If antibody levels decline to non-protective levels, it falls upon BM cells to mount a sufficiently rapid anamnestic response to limit the clinical consequence of exposure to virulent Shigella. Experimental challenge studies with immunologically-nai·ve healthy adult volunteers and epidemiologic investigations of point source outbreaks suggest that for most Shigella serotypes the usual incubation is -1-3 days from the point of ingestion of virulent organisms until the onset of clinical illness. Thus, an effective anamnestic response mediated by BM cells must occur within a mere 1-2 days. Few reports have directly addressed the duration of immunity that follows an initial clinical Shigella infection in the absence of repetitive boosting (as would occur in an endemic situation). Similarly, to our knowledge the only controlled studies that describe the duration of protection conferred by immunization with live oral Shigella vaccines were those of Mel et al. who immunized children living in an endemic area where Shigella was highly seasonal [43, 44] . Oral immunization with four doses over two weeks of streptomycin-dependent live oral Shigella vaccines led to significant serotype-homologous protection that endured for one year [44] . However, the administration of just a single oral booster dose was able to prolong the protection for an additional year [44] .
In summary, oral vaccination with a single oral dose of a liveattenuated Shigella vaccine elicited antigen-specific lgA BM responses among lgA seroresponders and slgA mucosal responders with a high degree of correlation between antigen-specific BM cells and both serum and mucosal titers as well as antigen-specific ASC in peripheral circulation. Mucosal slgA responses are more difficult to measure than serum antibody, as is the measurement of small number of lgA BM cells. Nevertheless, we observed positive correlations between antigenspecific anti-LPS BM cells and antigen-specific anti-LPS slgA/totallgA in stool. As Shigella invades via the gastrointestinal mucosa, fecal slgA responses likely play an important role as the first line of defense in protection. Antigen-specific lgA BM cells should be further studied in natural infection and challenge studies to determine their role in the anamnestic responses and protection against this important and devastating pathogen. For expedited identification of future candidate vaccines, it will be necessary to identify reliable surrogates of protection against symptomatic infection. A strong correlation between anti-LPS lgA BM cells and peak anti-LPS lgA antibody and ASC responses further reinforces our contention that BM cells may be an important indicator for long-term humoral immunity and a possible surrogate of protection against shigellosis.
Conclusions
Oral vaccination with live-attenuated S. flexneri 2a elicited detectable lgA BM cells to LPS and, to a lesser extent, to lpaB. Positive correlations were observed between anti-LPS lgA BM and both anti-LPS secretory lgA /total lgA in stool and anti-LPS lgA in serum as well as circulating ASC. In addition, flow cytometric analyses revealed significant differences in lgA• BM subsets expressing integrin a 4 /p. 7 pre to post vaccination when comparing seroresponders to non-responders. Our results support the contention that BM cells may be an important indicator for long-term humoral immunity and a possible surrogate of protection against shigellosis.
